| Year |
Citation |
Score |
| 2020 |
Sikder S, Kaypee S, Kundu TK. Regulation of epigenetic state by non-histone chromatin proteins and transcription factors: Implications in disease. Journal of Biosciences. 45. PMID 31965993 DOI: 10.1007/S12038-019-9974-3 |
0.658 |
|
| 2019 |
Ghosh R, Kaypee S, Shasmal M, Kundu TK, Roy S, Sengupta J. Tumor suppressor p53-mediated structural reorganization of the transcriptional coactivator p300. Biochemistry. PMID 31314496 DOI: 10.1021/Acs.Biochem.9B00333 |
0.638 |
|
| 2019 |
Deota S, Rathnachalam S, Namrata K, Boob M, Fulzele A, Radhika S, Ganguli S, Balaji C, Kaypee S, Vishwakarma KK, Kundu TK, Bhandari R, de Peredo AG, Mishra M, Venkatramani R, et al. Allosteric Regulation of Cyclin-B Binding by the Charge State of Catalytic Lysine in CDK1 Is Essential for Cell Cycle Progression. Journal of Molecular Biology. PMID 30974121 DOI: 10.1016/J.Jmb.2019.04.005 |
0.562 |
|
| 2018 |
Kaypee S, Sahadevan SA, Patil S, Ghosh P, Roy NS, Roy S, Kundu TK. Mutant and Wild-Type Tumor Suppressor p53 Induces p300 Autoacetylation. Iscience. 4: 260-272. PMID 30240745 DOI: 10.1016/J.Isci.2018.06.002 |
0.628 |
|
| 2018 |
Senapati P, Dey S, Sudarshan D, Das S, Kumar M, Kaypee S, Mohiyuddin A, Kodaganur GS, Kundu TK. Oncogene c-fos and mutant R175H p53 regulate expression of Nucleophosmin implicating cancer manifestation. The Febs Journal. PMID 30085406 DOI: 10.1111/Febs.14625 |
0.637 |
|
| 2018 |
Kaypee S, Sahadevan SA, Sudarshan D, Sinha SH, Patil S, Senapati P, Kodaganur GS, Mohiyuddin A, Dasgupta D, Kundu TK. Oligomers of human histone chaperone NPM1 alter p300/KAT3B folding to induce autoacetylation. Biochimica Et Biophysica Acta. PMID 29746960 DOI: 10.1016/J.Bbagen.2018.05.003 |
0.711 |
|
| 2018 |
Babu A, Kamaraj M, Basu M, Mukherjee D, Kapoor S, Ranjan S, Swamy MM, Kaypee S, Scaria V, Kundu TK, Sachidanandan C. Chemical and genetic rescue of an ep300 knockdown model for Rubinstein Taybi syndrome in zebrafish. Biochimica Et Biophysica Acta. PMID 29409755 DOI: 10.1016/J.Bbadis.2018.01.029 |
0.527 |
|
| 2016 |
Kaypee S, Sudarshan D, Shanmugam MK, Mukherjee D, Sethi G, Kundu TK. Aberrant Lysine Acetylation in Tumorigenesis: Implications in the Development of Therapeutics. Pharmacology & Therapeutics. PMID 26808162 DOI: 10.1016/J.Pharmthera.2016.01.011 |
0.631 |
|
| 2015 |
Naiya G, Kaypee S, Kundu TK, Roy S. A Constrained Helical Peptide Against S100A4 Inhibits Cell Motility in Tumor Cells. Chemical Biology & Drug Design. PMID 25763457 DOI: 10.1111/Cbdd.12553 |
0.496 |
|
| 2015 |
Wu M, Kim SH, Datta I, Levin A, Dyson G, Li J, Kaypee S, Swamy MM, Gupta N, Kwon HJ, Menon M, Kundu TK, Reddy GP. Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice. Oncotarget. 6: 6136-50. PMID 25704883 DOI: 10.18632/Oncotarget.3346 |
0.537 |
|
| 2015 |
Kaypee S, Mandal S, Chatterjee S, Kundu TK. Emerging Epigenetic Therapies: Lysine Acetyltransferase Inhibitors. Lysine Acetyltransferase Inhibitors. Epigenetic Cancer Therapy. 471-494. DOI: 10.1016/B978-0-12-800206-3.00021-5 |
0.495 |
|
| 2014 |
Vasudevarao MD, Mizar P, Kumari S, Mandal S, Siddhanta S, Swamy MM, Kaypee S, Kodihalli RC, Banerjee A, Naryana C, Dasgupta D, Kundu TK. Naphthoquinone-mediated inhibition of lysine acetyltransferase KAT3B/p300, basis for non-toxic inhibitor synthesis. The Journal of Biological Chemistry. 289: 7702-17. PMID 24469461 DOI: 10.1074/Jbc.M113.486522 |
0.584 |
|
| Show low-probability matches. |